You are here

Cancer Res DOI:10.1158/0008-5472.CAN-18-2711

A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.

Publication TypeJournal Article
Year of Publication2019
AuthorsHayes, TK, Luo, F, Cohen, O, Goodale, AB, Lee, Y, Pantel, S, Bagul, M, Piccioni, F, Root, DE, Garraway, LA, Meyerson, M, Johannessen, CM
JournalCancer Res
Volume79
Issue9
Pages2352-2366
Date Published2019 May 01
ISSN1538-7445
Abstract

Combinatorial inhibition of MEK1/2 and CDK4/6 is currently undergoing clinical investigation in NRAS-mutant melanoma. To prospectively map the landscape of resistance to this investigational regimen, we utilized a series of gain- and loss-of-function forward genetic screens to identify modulators of resistance to clinical inhibitors of MEK1/2 and CDK4/6 alone and in combination. First, we identified NRAS-mutant melanoma cell lines that were dependent on NRAS for proliferation and sensitive to MEK1/2 and CDK4/6 combination treatment. We then used a genome-scale ORF overexpression screen and a CRISPR knockout screen to identify modulators of resistance to each inhibitor alone or in combination. These orthogonal screening approaches revealed concordant means of achieving resistance to this therapeutic modality, including tyrosine kinases, RAF, RAS, AKT, and PI3K signaling. Activated KRAS was sufficient to cause resistance to combined MEK/CDK inhibition and to replace genetic depletion of oncogenic NRAS. In summary, our comprehensive functional genetic screening approach revealed modulation of resistance to the inhibition of MEK1/2, CDK4/6, or their combination in NRAS-mutant melanoma. SIGNIFICANCE: These findings reveal that NRAS-mutant melanomas can acquire resistance to genetic ablation of or combination MEK1/2 and CDK4/6 inhibition by upregulating activity of the RTK-RAS-RAF and RTK-PI3K-AKT signaling cascade.

DOI10.1158/0008-5472.CAN-18-2711
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/30819666?dopt=Abstract

Alternate JournalCancer Res.
PubMed ID30819666